SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Geneva: WHO, 2012.
  • 2
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095128.
  • 3
    Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011; 18(Suppl. 1): 116.
  • 4
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 16785.
  • 5
    Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 16778.
  • 6
    Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 50916.
  • 7
    van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 258493.
  • 8
    European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 9
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392420.
  • 10
    Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18: 60609.
  • 11
    Wedemeyer H. Hepatitis C in 2012: on the fast track towards IFN-free therapy for hepatitis C? Nat Rev Gastroenterol Hepatol 2013; 10: 768.
  • 12
    Deuffic-Burban S, Mathurin P, Valleron AJ. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res 2009; 18: 23352.
  • 13
    Sypsa V, Touloumi G, Papatheodoridis GV, et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005; 12: 54350.
  • 14
    Cohen C, Holmberg SD, McMahon BJ, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 2011; 18: 37783.
  • 15
    McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl. 1): 1516.
  • 16
    Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 2012; 26: 37180.
  • 17
    Angeli E, Mainini A, Meraviglia P, et al. Eligibility and feasibility of the treatment of chronic hepatitis C in a cohort of Italian HIV-positive patients at a single HIV reference center. AIDS Patient Care STDS 2011; 25: 295301.
  • 18
    Antonucci G, Mazzotta F, Puoti M, et al. Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. J Viral Hepat 2012; 19: 8819.
  • 19
    Backmund M, Meyer K, Von ZM, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 18893.
  • 20
    Cacoub P, Halfon P, Rosenthal E, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: modifications in two large surveys between 2004 and 2006. J Hepatol 2008; 48: 3542.
  • 21
    Cullen W, Stanley J, Langton D, Kelly Y, Bury G. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative. Eur J Gen Pract 2007; 13: 512.
  • 22
    Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17: 43543.
  • 23
    Delwaide J, El SR, Gerard C, Belaiche J. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005; 17: 11859.
  • 24
    Ena J, Ruiz-de-Apodaca RF, Pasquau F, Amador C, Benito C. Cross-sectional epidemiology of hepatitis C virus detection and treatment in HIV-infected patients. Eur J Intern Med 2011; 22: 6672.
  • 25
    Gazdag G, Horvath G, Szabo O, Ungvari GS. Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacol Hung 2010; 12: 45962.
  • 26
    Gheorghe L, Pascu O, Ceausu E, et al. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009. J Gastrointestin Liver Dis 2010; 19: 1617.
  • 27
    Hatem C, Minello A, Bresson-Hadni S, et al. Is the management of hepatitis C patients appropriate? A population-based study Aliment Pharmacol Ther 2005; 21: 100715.
  • 28
    Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 2331.
  • 29
    Lutgehetmann M, Meyer F, Volz T, et al. Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany. Z Gastroenterol 2010; 48: 112632.
  • 30
    Mocroft A, Rockstroh J, Soriano V, et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38: 10927.
  • 31
    Monnet E, Collin-Naudet E, Bresson-Hadni S, et al. Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study. J Hepatol 2006; 44: 499506.
  • 32
    Overbeck K, Bruggmann P, Helbling B. Chronic hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment? Eur J Gen Pract 2011; 17: 1038.
  • 33
    Papadopoulos N, Manolakopoulos S, Deutsch M, et al. Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol 2013; 25: 58793.
  • 34
    Parkes J, Roderick P, Bennett-Lloyd B, Rosenberg W. Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom. BMC Public Health 2006; 6: 3.
  • 35
    Sene D, Pol S, Piroth L, et al. Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study. Epidemiol Infect 2007; 135: 40916.
  • 36
    Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol 2009; 81: 19992006.
  • 37
    Stroffolini T, D'Egidio PF, Aceti A, et al. Hepatitis C virus infection among drug addicts in Italy. J Med Virol 2012; 84: 160812.
  • 38
    Stroffolini T, Spadaro A, Di Marco V, et al. Current practice of chronic hepatitis B treatment in Southern Italy. Eur J Intern Med 2012; 23: e1247.
  • 39
    Stroffolini T, Spadaro A, Guadagnino V, et al. Current practice of hepatitis C treatment in Southern Italy. Dig Liver Dis 2010; 42: 8225.
  • 40
    Tedder RS, Rodger AJ, Fries L, et al. The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis 2013; 56: 95160.
  • 41
    Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010; 2010: DOI:10.1155/2010/261472. Article ID 261472.
  • 42
    Mitchell AE, Colvin HM, Palmer BR. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 72933.
  • 43
    Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012; 6: 28595.
  • 44
    Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56: 3205.
  • 45
    Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14: 690210.
  • 46
    Leblebicioglu H, Arama V, Causse X, et al. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat 2014; 21: 662670.
  • 47
    Giannousis IP, Papatheodoridis GV, Deutsch MJ, et al. The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. Eur J Gastroenterol Hepatol 2010; 22: 1729.
  • 48
    Chu JJ, Wormann T, Popp J, et al. Changing epidemiology of hepatitis B and migration – a comparison of six Northern and North-Western European countries. Eur J Public Health 2013; 23: 6427.
  • 49
    Talal AH, LaFleur J, Hoop R, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013; 37: 47381.
  • 50
    Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 57183.
  • 51
    Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 113744.
  • 52
    Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(Suppl. 2): S3945.
  • 53
    Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598609.